In particular, tell your provider if you have a past history of: Type 1 or type 2 diabetes Thyroid cancer Pancreatitis Kidney disease Diabetic retinopathy Tell your provider if you are pregnant, planning to become pregnant, or breastfeeding
7 Cardiovascular Event Risk Reduction In patients with existing cardiovascular (CV) disease and either overweight or obesity, GLP1 receptor agonists have been approved by the U.S
S.DriessenA.GreveJ
If pralidoxime is administered before adequate atropinization , it may temporarily worsen life-threatening muscarinic effects, including: Bronchoconstriction Increased respiratory secretions , which can lead to airway obstruction Therefore, clinical guidelines recommend administering atropine before pralidoxime , and this sequence is reflected in autoinjector design (Aman et al., 2021
1 Patients with type 2 diabetes mellitus (T2DM) pathophysiology includes high glucose toxicity, lipotoxicity and insulin resistance
Rice DC, Swisher SG , Correa AM, Ajani JA, Putnam JB, Smythe WR, Walsh GL, Vaporciyan AA, Roth JA